Drugs which inhibit epidermal growth factor receptor (EGFR) are used in the treatment of cancers. EGFR may contribute to the development of hypertension by regulating vascular tone and renal Na+ handling. Synthetic EGFR inhibitors reduce blood pressure in some experimental models of hypertension suggesting that this receptor is a novel target for antihypertensive therapy.
Keywords: Epidermal growth factor receptor, arterial hypertension, receptor transactivation, extracellular signal-regulated kinases, receptor tyrosine kinase inhibitors, leptin, metabolic syndrome
Rights & PermissionsPrintExport